Accuray Stock Down as Q4 Earnings Miss Estimates, Revenues Down Y/Y
ARAY stock down after Q4 earnings miss estimates, with product sales hit by tariffs and regional demand softness.
Accuray Q4 Revenue Hits $128 Million
Accuray reported fourth-quarter fiscal 2025 results on August 13, 2025, with $128 million in revenue ( down 5% year-over-year ) , service revenue of $56.9 million ( up 4% year-over-year ) , and adjusted EBITDA of $9.4 million.
Accuray ( ARAY ) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, August 13, 2025 at 4:30 p.m. ETPresident and Chief Executive Officer - Suzanne WinterContinue reading ...
Accuray ( ARAY ) Reports Break-Even Earnings for Q4
Accuray (ARAY) delivered earnings and revenue surprises of -100.00% and +2.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
NeuroPace, Inc. ( NPCE ) Reports Q2 Loss, Beats Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of -8.33% and +0.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Astrana Health, Inc. ( ASTH ) Q2 Earnings Lag Estimates
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -47.22% and +2.31%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics ( KIDS ) Reports Q2 Loss, Misses Revenue Estimates
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +35.29% and -1.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY rides strong global demand and CyberKnife momentum, but order declines and backlog pressure temper the outlook.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities - Accuray ( NASDAQ:ARAY )
MADISON, Wis., June 6, 2025 /PRNewswire/ -- Accuray Incorporated ARAY today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its ...
Why Is Accuray ( ARAY ) Up 17% Since Last Earnings Report?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.
Accuray ( ARAY ) Reports Q3 Loss, Tops Revenue Estimates
Accuray (ARAY) delivered earnings and revenue surprises of 80% and 10.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher ( TMO ) Surges 8.2%: Is This an Indication of Further Gains?
Thermo Fisher (TMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results
• Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023 • Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023 • U.S.
Accuray ( ARAY ) Down 32% Since Last Earnings Report: Can It Rebound?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up
Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses.
Accuray ( ARAY ) Q2 Earnings and Revenues Top Estimates
Accuray (ARAY) delivered earnings and revenue surprises of 300% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
GEHC Stock Gains on the Collaborated Launch of Care Innovation Hub
GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.
TMDX Stock Down Despite Responding to Misleading Short-Seller Report
TransMedics addresses the misleading claims made in a short-seller report issued by Scorpion Capital.
Accuray ( ARAY ) Shows Fast-paced Momentum But Is Still a Bargain Stock
Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
Reasons to Add GE HealthCare Stock to Your Portfolio Now
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
GEHC Stock Gains on Long-Term Collaboration With Sutter Health
GE HealthCare announces a seven-year strategic collaboration with Sutter Health.
Cardinal Health Stock May Gain With New Texas Distribution Center
CAH announces the ongoing construction of a new distribution center in Texas, which is likely to support its at-Home Solutions business.
Intuitive Surgical Stock Surges on Q4 Preliminary Revenue Beat
ISRG records significant growth in the top line, driven by higher system placements as well as improved pricing. Procedure volume remains strong.
PACB Stock Declines Despite Promising HiFi Sequencing Findings
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.
GKOS Stock Gains Following Positive Study Data on iDose Platform
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions
Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.
DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.
TEM Stock Declines Following Preliminary Q4 Sales Miss
Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.
PacBio Stock May Gain Following the Collaborated Launch of GutID
PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Are Medical Stocks Lagging Aptevo Therapeutics ( APVO ) This Year?
Here is how Aptevo Therapeutics Inc. (APVO) and Accuray (ARAY) have performed compared to their sector so far this year.
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics
PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.
EDAP Appoints Joshua H. Levine to Board of Directors
PDF Version ...
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis
TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.
Here's Why You Should Add Accuray Stock to Your Portfolio Now
ARAY's solid product demand and revenue growth raise optimism about the stock.
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test
Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.
Stryker Stock Falls Despite the Agreement to Acquire Inari Medical
SYK inks an agreement to acquire Inari Medical at a valuation of approximately $4.9 billion.
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
TMCI Stock May Gain From the Limited Release of the Percuplasty System
Treace Medical announces the limited market release of the Percuplasty Percutaneous 3D Bunion Correction System, targeting the in-demand bunion surgery market.
Cencora Stock May Gain Following the Strategic Acquisition of RCA
COR completes the acquisition of Retina Consultants of America, marking a significant step in expanding its specialty healthcare and MSO solutions.
Reasons to Add Cardinal Health Stock to Your Portfolio Now
CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.
